HC Wainwright Issues Pessimistic Estimate for SPRO Earnings

Spero Therapeutics, Inc. (NASDAQ:SPRO) – Research analysts at HC Wainwright lowered their FY2024 earnings estimates for Spero Therapeutics in a report released on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($1.23) for the year, down from their previous estimate of ($0.75). HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Spero Therapeutics’ current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Spero Therapeutics’ Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.84) EPS.

Several other research firms have also recently issued reports on SPRO. TD Cowen reissued a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th.

Spero Therapeutics Stock Performance

SPRO opened at $1.16 on Wednesday. The company’s 50 day simple moving average is $1.25 and its 200 day simple moving average is $1.32. Spero Therapeutics has a 1 year low of $1.01 and a 1 year high of $1.89. The stock has a market capitalization of $63.24 million, a PE ratio of 16.57 and a beta of 0.59.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Spero Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after purchasing an additional 9,675 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Spero Therapeutics during the first quarter worth $31,000. Renaissance Technologies LLC lifted its position in shares of Spero Therapeutics by 14.2% during the second quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after purchasing an additional 121,492 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in shares of Spero Therapeutics by 40.6% in the second quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company’s stock worth $1,392,000 after buying an additional 309,262 shares during the last quarter. 25.60% of the stock is owned by institutional investors and hedge funds.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.